EP2370819A4 - Diagnostic and treatment methods for cancer based on immune inhibitors - Google Patents

Diagnostic and treatment methods for cancer based on immune inhibitors

Info

Publication number
EP2370819A4
EP2370819A4 EP09830987A EP09830987A EP2370819A4 EP 2370819 A4 EP2370819 A4 EP 2370819A4 EP 09830987 A EP09830987 A EP 09830987A EP 09830987 A EP09830987 A EP 09830987A EP 2370819 A4 EP2370819 A4 EP 2370819A4
Authority
EP
European Patent Office
Prior art keywords
diagnostic
treatment methods
cancer based
immune inhibitors
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09830987A
Other languages
German (de)
French (fr)
Other versions
EP2370819A2 (en
Inventor
Mathias Oelke
Jonathan Schneck
Tonya Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP2370819A2 publication Critical patent/EP2370819A2/en
Publication of EP2370819A4 publication Critical patent/EP2370819A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides
EP09830987A 2008-12-01 2009-12-01 Diagnostic and treatment methods for cancer based on immune inhibitors Withdrawn EP2370819A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11881708P 2008-12-01 2008-12-01
US17597709P 2009-05-06 2009-05-06
PCT/US2009/066262 WO2010065544A2 (en) 2008-12-01 2009-12-01 Diagnostic and treatment methods for cancer based on immune inhibitors

Publications (2)

Publication Number Publication Date
EP2370819A2 EP2370819A2 (en) 2011-10-05
EP2370819A4 true EP2370819A4 (en) 2012-09-19

Family

ID=42233821

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09830987A Withdrawn EP2370819A4 (en) 2008-12-01 2009-12-01 Diagnostic and treatment methods for cancer based on immune inhibitors

Country Status (3)

Country Link
US (1) US20110256147A1 (en)
EP (1) EP2370819A4 (en)
WO (1) WO2010065544A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536140B2 (en) * 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
CA2818536C (en) 2010-11-25 2020-04-28 Imnate Sarl Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells
RU2598247C2 (en) 2010-11-25 2016-09-20 Имнейт Сарл Modulation of antigen immunogenicity by deleting epitopes recognized by nkt-cells
WO2015051247A1 (en) * 2013-10-03 2015-04-09 University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of nkt cells
US20170058353A1 (en) * 2014-02-12 2017-03-02 Tonya J Webb Qpcr-based method to assess t cell function
KR20210032011A (en) * 2014-09-17 2021-03-23 더 존스 홉킨스 유니버시티 Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
MX2021005372A (en) 2018-11-08 2021-09-14 Neximmune Inc T cell compositions with improved phenotypic properties.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091005A1 (en) * 1982-04-02 1983-10-12 Sloan-Kettering Institute For Cancer Research Method for detecting the presence of GD3 ganglioside

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US5006470A (en) * 1987-04-16 1991-04-09 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens of melanoma
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
JPWO2002078739A1 (en) * 2001-03-29 2004-07-22 協和醗酵工業株式会社 Pharmaceutical containing a recombinant antibody against ganglioside GD3
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091005A1 (en) * 1982-04-02 1983-10-12 Sloan-Kettering Institute For Cancer Research Method for detecting the presence of GD3 ganglioside

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARIGA TOSHIO ET AL: "Glycosphingolipid antigens in neural tumor cell lines and anti-glycosphingolipid antibodies in sera of patients with neural tumors", NEUROSIGNALS, KARGER, BASEL; CH, vol. 16, no. 2-3, 1 January 2008 (2008-01-01), pages 226 - 234, XP009137122, ISSN: 1424-862X, [retrieved on 20080205], DOI: 10.1159/000111565 *
GUIDO KOHLA ET AL: "Gangliosides with O-Acetylated Sialic Acids in Tumors of Neuroectodermal Origin", NEUROCHEMICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 27, no. 7-8, 1 August 2002 (2002-08-01), pages 583 - 592, XP019289512, ISSN: 1573-6903 *
MEPUR H. RAVINDRANATH ET AL: "Ganglioside GM3:GD3 ratio as an index for the management of melanoma", CANCER, vol. 67, no. 12, 15 June 1991 (1991-06-15), pages 3029 - 3035, XP055034874, ISSN: 0008-543X, DOI: 10.1002/1097-0142(19910615)67:12<3029::AID-CNCR2820671217>3.0.CO;2-8 *
SCAMBIA G ET AL: "A primary amelanotic melanoma of the vagina diagnosed by immunocytochemistry", INTERNATIONAL JOURNAL OF GYNECOLOGY AND OBSTETRICS, NEW YORK, NY, US, vol. 29, no. 2, 1 June 1989 (1989-06-01), pages 159 - 164, XP026260402, ISSN: 0020-7292, [retrieved on 19890601], DOI: 10.1016/0020-7292(89)90847-3 *

Also Published As

Publication number Publication date
WO2010065544A3 (en) 2010-09-16
US20110256147A1 (en) 2011-10-20
WO2010065544A2 (en) 2010-06-10
EP2370819A2 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
IL213070A0 (en) Methods for the treatment of infections and tumors
HK1148906A1 (en) Compositions and methods for cancer treatment
EP2170180A4 (en) Methods and apparatuses for vascular and prostate treatment
EP2318406A4 (en) Thiosemicarbazone inhibitor compounds and cancer treatment methods
IL216013A0 (en) Devices and methods for dermatological treatment
EP2340851A4 (en) Diagnosis method and therapeutic method for cancer
GB0802402D0 (en) Medical device and method
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP2125887A4 (en) Compositions and methods for diagnosing and treating cancer
GB0922085D0 (en) Cancer diagnosis and treatment
EP2652506A4 (en) The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer
EP2480687A4 (en) Methods and compositions for the diagnosis and treatment of thyroid cancer
GB0819280D0 (en) Imgaing and radiotherapy methods
GB0604471D0 (en) Device and method for the treatment of tumours
EP2340027A4 (en) Methods and compositions for the treatment of cancer
EP2171086A4 (en) Methods of diagnosing and treating cancer
GB0807018D0 (en) Antibodies and treatment
GB0802277D0 (en) Medical device and method
IL238394A0 (en) Cancer treatment method
EP2370819A4 (en) Diagnostic and treatment methods for cancer based on immune inhibitors
GB0918392D0 (en) Diagnostic and therapeutic methods
HK1212218A1 (en) Organoarsenic compounds and methods for the treatment of cancer
EP2198041A4 (en) Method and composition for cancer diagnosis and treatment
PT2630475T (en) Diagnostic method and treatment
EP2361317A4 (en) Use of eif3m for the diagnosis and treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110630

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120821

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/15 20060101ALI20120814BHEP

Ipc: G01N 33/574 20060101ALI20120814BHEP

Ipc: G01N 33/50 20060101AFI20120814BHEP

Ipc: G01N 33/92 20060101ALI20120814BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130319